Bristol Myers price target raised to $60 from $54 at Leerink

3 days ago 3

TipRanks

Wed, January 14, 2026 astatine 8:16 AM CST 1 min read

Leerink expert David Risinger raised the firm’s price target connected Bristol Myers (BMY) to $60 from $54 and keeps an Outperform standing connected the shares. The steadfast sees important pipeline optionality successful 2026 and frankincense country for further banal upside potential. Leerink notes the institution provided an overview of its pipeline readouts to ticker successful 2026 and beyond astatine a league connected January 12, 2026. The institution has 12 registrational information readouts from 8 assets anticipated successful 2026, astir of which correspond important caller motorboat opportunities successful coming years. The steadfast believes investors heavy discount astir pipeline candidates, frankincense yielding important upside if immoderate cards crook retired to beryllium positive.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected BMY:

Disclaimer & DisclosureReport an Issue

Bristol-Myers Squibb Advances Liver Cancer Combo arsenic Key Trial Reaches Completion
Bristol Myers Squibb Showcases Growth Strategy astatine JPM Conference
BioNTech outlines 2026 areas of focus
Bristol Myers announces ‘positive’ results from Phase 3 SCOUT-HCM trial
Tempus AI (TEM) Tops $1.1B successful Total Contract Value arsenic Pharma Demand for AI Tools Surges

Read Entire Article